Replies to post #54956 on Biotech Values

[DewDiligence]

>MNTA – I would like to see them move M118 ahead as fast as feasible.<

Let’s recap the M118 development milestones to date:

Jul 06: IND filed
Oct 06: Phase-1 started for IV formulation
May 07: Phase-1 started for sub-Q formulation
Oct 07: Phase-2 started in stable angina

It looks like MNTA has been moving this compound forward with expedition.

Should MNTA partner M118 now to run a large phase-2 program in multiple indications… or should MNTA keep the drug in-house until there are phase-2 efficacy data in order to aim for better economic terms?

I lean toward partnering now.